anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Parkinson's disease (PD) is one of the complex neurodegenerative disorders, primarily characterized by motor deficits, including bradykinesia, tremor, rigidity, and postural instability. The underlying pathophysiology involves the progressive loss of dopaminergic neurons within the substantia nigra pars compacta, leading to dopamine depletion in the basal ganglia circuitry. While motor symptoms are hallmark features of PD, emerging research highlights a wide range of non-motor symptoms, including cognitive impairments, mood disturbances, and autonomic dysfunctions. Inflammasome activation is pivotal in inducing neuroinflammation and promoting disease onset, progression, and severity of PD. Several studies have shown that long noncoding RNAs (lncRNAs) modulate inflammasomes in the pathogenesis of neurodegenerative diseases. Dysregulation of lncRNAs is linked to aberrant gene expression and cellular processes in neurodegeneration, causing the activation of inflammasomes that contribute to neuroinflammation and neurodegeneration. Inflammasomes are cytosolic proteins that form complexes upon activation, inducing inflammation and neuronal cell death. This review explores the significance of lncRNAs in regulating inflammasomes in PD, primarily focusing on specific lncRNAs such as nuclear paraspeckle assembly transcript 1 (NEATNEAT1), X-inactive specific transcript (XIST), growth arrest-specific 5 (GAS5), and HOX transcript antisense RNA (HOTAIR), which have been shown to activate or inhibit the NLRP3 inflammasome and induce the release of proinflammatory cytokines. Moreover, some lncRNAs mediate inflammasome activation through miRNA interactions. Understanding the roles of lncRNAs in inflammasome regulation provides new therapeutic targets for controlling neuroinflammation and reducing the progression of neurodegeneration. Identifying lncRNA-mediated regulatory pathways paves the way for novel therapies in the battle against these devastating neurodegenerative disorders.
The optimised insulin infusion system consisted in regular human insulin administration through a multilumen device (Edelvaiss Multiline-8, Doran International, Toussieu, France). This device had ports for eight infusions which run through separate channels within a 150 cm flexible plastic tube. Since fluids from the individual channels do not meet until they exit the distal tip. Carrier was infused through the high flow (HF) line and insulin was infused by syringe pump systematically next to the HF line port. All others medicines were administered via adjacent ports on the Multiline-8.
PURPOSE: To obtain a solid pharmaceutical preparation improved in bitterness of a H2 blocker without using complicate producing method having many step numbers and using an organic solvent and readily applicable. CONSTITUTION: This H2 blocker solid pharmaceutical agent improved in bitter taste and readily applicable is obtained by adding a sugar alcohol having -60KJ/kg, preferably <=-100KJ/kg heat of solution, e.g. xylitol, sorbitol or erythritol. The sugar alcohol is preferably added in an amount of >=25 pts.wt. preferably >=40 pts.wt. based on 1 pt.wt. of H2 blocker and preferably added in an amount of 50-99.9%, preferably 80-99.9% based on total weight of the pharmaceutical preparation. The bitterness improving effect is further improved by adding <=1%, preferably <=0.1% 1-menthol to the pharmaceutical preparation. Especially, famotidine is preferably used as H2 blocker. A method for producing the pharmaceutical preparation includes e.g. granulating a sugar alcohol and powdered H2 blocker by fluid layer granulator using an aqueous solution of a binder according to an ordinary method, controlling granule to desired particle diameter, blending the granule with powdered 1-menthol and a fluidizing agent in a blending machine and preparing the blend.
BACKGROUND: Traumatic hip dislocation is a rare yet severe injury. As the long-term morbidity, subsequent complications, and clinical outcomes are nearly unknown, we aimed to analyze traumatic hip dislocations and identify specific factors that may predict the clinical outcome.
METHODS: Data on injury-related characteristics and computed tomographic (CT) scans for all consecutive adult patients who had been managed for traumatic hip dislocation between 2009 and 2021 were analyzed. At the time of follow-up, the patients were assessed with regard to osteonecrosis, posttraumatic osteoarthritis (OA), further operations and complications, return to sports and work, and patient-reported outcome measures (PROMs), including the Tegner Activity Scale and modified Harris hip score.
RESULTS: One hundred and twelve patients (mean age [and standard deviation], 43.12 ± 16.6 years) were included. Associated acetabular rim and femoral head fractures (Pipkin Type I to IV) were observed in 44% and 40% of patients, respectively. Concomitant injuries occurred in 67% of the patients, most commonly involving the knee (29% of patients). Sixty-nine patients (61.6%) were available for follow-up; the mean duration of follow-up was 6.02 ± 3.76 years. The rates of osteonecrosis and posttraumatic OA were 13% and 31.9%, respectively, and were independent of the timing of hip reduction, leading to subsequent total hip arthroplasty (THA) in 19% of patients. Sciatic nerve injury occurred in 27.5% of the patients who were available for follow-up. Both THA and sciatic nerve injury were associated with posterior acetabular rim or Pipkin Type-IV fractures (p < 0.001). Only 33.3% of the patients returned to their pre-injury level of sports, 24.6% did not return to work, and 27.5% reported having sexual dysfunction. PROMs (Tegner Activity Scale, modified Harris hip score) were significantly worse in patients with osteonecrosis, posttraumatic OA, or residual sciatic nerve injury (p < 0.05).
CONCLUSIONS: Traumatic hip dislocations are predominantly associated with Pipkin and acetabular rim fractures, leading to overall limitations of activities of daily living, sports, and sexual function at intermediate to long-term follow-up. Patients with associated acetabular rim or Pipkin Type-IV fractures are most likely to require THA for the treatment of osteonecrosis or posttraumatic OA and are at greater risk for sustaining sciatic nerve injury.
LEVEL OF EVIDENCE: Prognostic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Diabetic peripheral neuropathy (DPN) is caused by several factors, including reactive free oxygen radicals (ROS)-induced excessive Ca2+ influx. Transient receptor potential (TRP) vanilloid 4 (TRPV4) is a member of the Ca2+-permeable TRP superfamily. Resveratrol (RESV) has been extensively utilized in TRP channel regulation due to its pharmacological properties, which include antioxidant and TRP inhibitory effects. The protective function of RESV and the contribution of TRPV4 to streptozotocin (STZ)-induced neuropathic pain in mice are still unclear. Here, we evaluated the effects of RESV through the modulation of TRPV4 on Ca2+ influx, ROS-mediated pain, apoptosis, and oxidative damage in the mouse dorsal root ganglion (DRGs). From the 32 mice, four groups were induced: control, RESV, STZ, and STZ + RESV. We found that the injection of RESV reduced the changes caused by the STZ-induced stimulation of TRPV4, which in turn increased mechanical/thermal neuropathic pain, cytosolic Ca2+ influx, TRPV4 current density, oxidants (lipid peroxidation, mitochondrial ROS, and cytosolic ROS), and apoptotic markers (caspase-3, -8, and -9). The RESV injection also increased the STZ-mediated reduction of viability of DRG and the amounts of glutathione, glutathione peroxidase, vitamin A, β-carotene, and vitamin E in the brain, erythrocytes, plasma, liver, and kidney. All of these findings suggest that TRPV4 stimulation generates oxidative neurotoxicity, neuropathic pain, and apoptosis in the STZ-induced diabetic mice. On the other hand, neurotoxicity and apoptosis were reduced due to the downregulation of TRPV4 carried out through the RESV injection.
Subjects randomized to this arm will receive placebo capsules twice daily for 12 months. The capsules will contain riboflavin (vitamin B2).
The present invention provides a method for adjusting the yield and purity of a proteinase inhibitor extract from plant tissue, preferably potato tubers. The extraction and isolation of the proteinase inhibitor from potatoes begins with the addition of an organic acid, preferably formic acid, and a salt, preferably sodium chloride, to raw potatoes. The mixture is subjected to process steps to extract soluble proteins. The extract is subjected to heat treatment at an adjusted temperature and adjusted duration whereby purity of the proteinase inhibitor is enhanced by heating at a relatively high temperature for a relatively short duration and whereby yield of the proteinase inhibitor is enhanced by heating at a relatively low temperature for a relatively long duration. If the removal of soluble protein impurities that are not denatured during the heat treatment step is desired, ultrafiltration is used. By adjusting the cycles of filtration, purity of the proteinase inhibitor can be adjustably selected.
In his 1872 monograph, Charles Darwin posited that "… the habit of expressing our feelings by certain movements, though now rendered innate, had been in some manner gradually acquired."1 Nearly 150 years later, researchers are still teasing apart innate versus experience-dependent contributions to expression recognition. Indeed, studies have shown that face detection is surprisingly resilient to early visual deprivation,2,3,4,5 pointing to plasticity that extends beyond dogmatic critical periods.6,7,8 However, it remains unclear whether such resilience extends to downstream processing, such as the ability to recognize facial expressions. The extent to which innate versus experience-dependent mechanisms contribute to this ability has yet to be fully explored.9,10,11,12,13 To investigate the impact of early visual experience on facial-expression recognition, we studied children with congenital cataracts who have undergone sight-correcting treatment14,15 and tracked their longitudinal skill acquisition as they gain sight late in life. We introduce and explore two potential facilitators of late-life plasticity: the availability of newborn-like coarse visual acuity prior to treatment16 and the privileged role of motion following treatment.4,17,18 We find that early visual deprivation does not preclude partial acquisition of facial-expression recognition. While rudimentary pretreatment vision is sufficient to allow a low level of expression recognition, it does not facilitate post-treatment improvements. Additionally, only children commencing vision with high visual acuity privilege the use of dynamic cues. We conclude that skipping typical visual experience early in development and introducing high-resolution imagery late in development restricts, but does not preclude, facial-expression skill acquisition and that the representational mechanisms driving this learning differ from those that emerge during typical visual development.
The invention discloses a traditional Chinese medicine preparation for preventing and treating heat stroke. The traditional Chinese medicine preparation is prepared by adopting the following active ingredients in parts by weight: 9 to 16 parts of kummerowia striata, 7 to 12 parts of buckeye, 8 to 15 parts of Tibet lancea, 12 to 18 parts of bamboo leaves, 7 to 14 parts of cavaleriei var. simplicifolia, 8 to 13 parts of amesia mairei, 10 to 15 parts of pteris ensiformis burm, 8 to 16 parts of ficus pandurta hance, 9 to 15 parts of rabdosia rubescens, 7 to 16 parts of plumeria rubra, 6 to 12 parts of melothria heterophylla, 9 to 14 parts of clethra loosestrife herb, 11 to 15 parts of salvia plebeia and 8 to 17 parts of Chinese mesona herb. The traditional Chinese medicine preparation is prepared by selecting traditional Chinese medicinal plant materials, is safe and non-toxic, has no side effect and is wide in application range. The formula completely satisfies the principle of syndrome differentiation and treatment of the traditional Chinese medicine. The traditional Chinese medicine preparation for preventing and treating the heat stroke has functions for clearing away the internal heat, removing the toxicity, invigorating the Qi, soothing the middle and the like and has advantages of wide medicine source, low cost, fast effect, good curative effect and the like.
Personality traits of impulsivity will be measured with the Barrett Impulsiveness Scale and the NEO Personality Inventory-Revised. Behavioral components of impulsivity will be tested through delay and probability discounting tasks. Finally, measures of frontotemporal functioning are also included in a neuropsychology and neurocognitive battery. Recent studies have shown that these areas of the brain function differently in pathological gamblers; thus, the following neuropsychology/neurocognitive tests have been included: Attention/Information Processing Speed (via Simple Reaction Time Task and Continuous Performance Task), Episodic Memory (via Hopkins Verbal Learning Test-Revised and Brief Visuospatial Memory Test), Executive/Frontal Lobe Measures (via Wechsler Memory Scale-III, Choice Reaction Time Task, Working Memory Task (N-back), Probabilistic Reversal Learning Task, and Stop-Signal Task). Between group comparisons on this battery of impulsivity tests will be made to clarify which components of impulsivity are associated with pathological gambling. Secondly, within-group analyses will be performed to correlate impulsivity to gambling severity. Lastly, an exploratory analysis of subtyping pathological gamblers by performances on tasks of impulsivity and types of gambling will be conducted.
OBJECTIVE: Antidepressants are commonly used to treat bipolar depression but may increase the risk of mania. The evidence from randomized controlled trials, however, is limited by short treatment durations, providing little evidence for the long-term risk of antidepressant-induced mania. The authors performed a target trial emulation to compare the risk of mania among individuals with bipolar depression treated or not treated with antidepressants over a 1-year period.
METHODS: The authors emulated a target trial using observational data from nationwide Danish health registers. The study included 979 individuals with bipolar depression recently discharged from a psychiatric ward. Of these, 358 individuals received antidepressant treatment, and 621 did not. The occurrence of mania and bipolar depression over the following year was ascertained, and the intention-to-treat effect of antidepressants was analyzed by using Cox proportional hazards regression with adjustment for baseline covariates to emulate randomized open-label treatment allocation.
RESULTS: The fully adjusted analyses revealed no statistically significant associations between treatment with an antidepressant and the risk of mania in the full sample (hazard rate ratio=1.08, 95% CI=0.72-1.61), in the subsample concomitantly treated with a mood-stabilizing agent (hazard rate ratio=1.16, 95% CI=0.63-2.13), and in the subsample not treated with a mood-stabilizing agent (hazard rate ratio=1.16, 95% CI=0.65-2.07). Secondary analyses revealed no statistically significant association between treatment with an antidepressant and bipolar depression recurrence.
CONCLUSIONS: These findings suggest that the risk of antidepressant-induced mania is negligible and call for further studies to optimize treatment strategies for individuals with bipolar depression.
OBJECTIVE: To explore the timing of general anesthesia for pediatric patients who have recovered from novel coronavirus infection and summarize anesthesia-related complications.
METHODS: We summarized the perioperative management of children under 14 years of age who underwent general anesthesia in our hospital according to national epidemic prevention and control requirements. We compared the incidence of postoperative pulmonary complications within 2 weeks (Group A), 3-4 weeks (Group B), and 5-6 weeks (Group C) after COVID-19 recovery.
RESULTS: There were differences among the three groups in terms of decreased blood oxygen saturation (< 94%), secretions, and coughing during the PACU period. The risk of low blood oxygen saturation during PACU decreased as the time of COVID-19 recovery extended in the three groups. Compared to Group A, the risk of low blood oxygen saturation was lower in Group B. The presence of respiratory symptoms and a body temperature above 40℃ increased the risk of decreased blood oxygen saturation. The proportion of children aged 11-14 years and children with high fever experiencing decreased blood oxygen saturation during PACU was higher in Groups A and B. Among the three groups, children with respiratory symptoms and longer illness duration had a higher proportion of decreased blood oxygen saturation during PACU.
CONCLUSION: Pediatric patients who have recovered from COVID-19 for more than 2 weeks have a lower risk of postoperative complications after general anesthesia. For children with respiratory system symptoms or high fever, there is a higher risk of transient blood oxygen saturation decrease during PACU. For older children, those with high fever, respiratory system symptoms, or longer illness duration, it is recommended to appropriately extend the time from COVID-19 recovery to surgery.
BACKGROUND: A significant number of patients experience complications of the Kock pouch (KP) warranting revision or excision. This systematic review aimed to assess the pooled prevalence and risk factors for complications and failure of the KP.
METHODS: This Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)-compliant systematic review (CRD42023416961) searched PubMed, Scopus, and Web of Science for studies on adult patients with Kock continent ileostomy published after the year 2000. The main outcome measures were revision, complications, and failure of the KP. Risk factors for complications and failure were assessed using a meta-regression analysis. Risk of bias was assessed using the ROBINS-1 tool. A proportional meta-analysis of the main outcomes was performed.
RESULTS: A total of 19 studies (2042 patients) were included. The weighted mean prevalence of complications was 60.4% [95% confidence interval (CI): 46.1-74.7%], of pouch revision was 46.6% (95% CI: 38.5-54.7%), and of pouch failure was 12.9% (95% CI: 9.3-16.4%). Studies conducted in the USA had a mean failure prevalence of 12.6% (95% CI: 6.2-18.9%) comparable to studies conducted in Europe (11.1%; 95% CI: 7.5-14.7%). Factors associated with higher complications were increased body mass index (BMI) and previous ileoanal pouch anastomosis (IPAA); however, these factors were not associated with increased pouch failure.
CONCLUSIONS: The KP is a highly complex operation as shown by a pooled complication prevalence of 60%, and thus, it should be only performed by experienced surgeons. Despite the high prevalence of complications and need for revisional surgery, patients are keen to preserve their KP. Increased BMI and a previous failed IPAA are risk factors for pouch complications, but not failure.
PURPOSE:To provide a drug containing docosahexaenoic acid as an active ingredient, capable of specifically reducing LDL in plasma without being accom panied by the storage of cholesterol in a liver and further capable of reducing triglycerides in the plasma. CONSTITUTION:The objective agent contains as an active ingredient a purified product from a fish oil or a chemically synthesized product such as docosahexaenoic acid or a pharmaceutically acceptable salt (e.g. Na salt or Ksalt), ester (e.g. glyceride or ascorbic acid ester) or amide (e.g. a derivative bonded to an amino acid, peptide or protein through an amide bond) thereof. The agent is preferably compounded with an antioxidant such as butylhydroxytoluene, propyl gallate or alpha-tocopherol.
BACKGROUND: Levamisole is less expensive and has a better toxicity profile compared to other steroid sparing agents used in nephrotic syndrome. It has a plasma half-life of 2.0 to 5.6 hours, but is conventionally administered on alternate days. We aimed to assess whether daily levamisole is safe and more effective than standard alternate-day therapy in maintaining remission in children with frequently relapsing or steroid-dependent nephrotic syndrome (FR/SDNS).
METHODS: An open-label randomized controlled trial was conducted in children with FR/SDNS. Group A received daily while Group B received alternate-day levamisole (2-3 mg/kg/dose) for 12 months. Prednisolone was tapered off by 3 months. Patients were monitored for relapses, further steroid requirement, and adverse effects.
RESULTS: A total of 190 children with FR/SDNS (94 in Group A and 96 in Group B) were analyzed. Sustained remission for 12 months was observed in 36% of Group A and 27% of Group B patients (p = 0.18). Numbers completing 12 months in the study were 67% in Group A and 56% in Group B (p = 0.13). Time to first relapse, persistent FR/SDNS, and withdrawal due to poor compliance were statistically similar in both groups, while relapse rate and cumulative steroid dosage were significantly lower in Group A compared to Group B (p = 0.03 and p = 0.02, respectively). The incidence of adverse effects was comparable in both groups, with reversible leucopenia and hepatic transaminitis being the commonest.
CONCLUSIONS: Daily levamisole therapy was not superior to alternate-day therapy in maintaining sustained remission over 12 months. Nevertheless, relapse rate and cumulative steroid dosage were significantly lower without increased adverse effects.
The invention relates to the field of medical biotechnology, and specifically to the creation and production of natural virucidal disinfectants that are safe for human and animal health and the environment. A virucidal preparation is created on the basis of natural isoborneol. The virucidal preparation contains a virucidal agent; ethanol; a polymer component, polysorbite, which forms a complex with isoborneol; and water, wherein as the virucidal agent it contains isoborneol (in a first embodiment) or a mixture of borneol and isoborneol (in a second embodiment), with the following ratio of components: 0.01-10 wt% isoborneol or borneol-isoborneol mixture, 0.2-20 wt% ethanol, 0.05-10 wt% polysorbite, and the remainder water. The preparation according to either embodiment may also contain a perfume additive in an amount of 0.05-0.5 wt%. Furthermore, as the perfume additive the preparation may contain at least one essential oil selected from the group consisting of: geranium oil, lime oil, lemon oil, bergamot oil, lemon oil. The preparation according to either embodiment may take the form of a gel, or a spray, or an ointment, or a perfume, or a paste. The preparation is of natural origin, causes irreversible changes in a virus structure, has high bioavailability and does not irritate the skin or mucous membranes. It is safe when it enters the gastrointestinal tract and has a long shelf life.
Participants will be included in all pre-intervention and post-assessment measures. Participants will receive the Listening Project Protocol intervention. The duration of the intervention is approximately 45 minutes per day, for 5 consecutive days.